Use of gonadotropin-releasing hormone agonists in the treatment of hyperandrogenism.
Rittmaster
R S
RS
Dalhousie University, Halifax, Nova Scotia, Canada.
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000728:Androgens / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D006628:Hirsutism / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006946:Hyperinsulinism / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D010053:Ovary / Q000187:drug effects / Q000378:metabolism; D012738:Sex Hormone-Binding Globulin / Q000737:chemistry; D013739:Testosterone / Q000097:blood
D000728:Androgens; D012738:Sex Hormone-Binding Globulin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone